NKX3-2 and ovarian carcinoma: Additionally, Figure 4d, which includes survival data from TCGA database, suggested that higher NKX3-2 expression in patients receiving paclitaxel treatment is linked to a worse prognosis, potentially making NKX3-2 a valuable prognostic marker for ovarian cancer.